{
    "clinical_study": {
        "@rank": "13170", 
        "acronym": "REVAHS", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "no medication"
            }, 
            {
                "arm_group_label": "Resveratrol", 
                "arm_group_type": "Experimental", 
                "description": "Trans-resveratrol (Resveratrol - Terraternal\u00ae): 5 g (10 capsules) as single oral dose on day 1 of the investigation period."
            }
        ], 
        "brief_summary": {
            "textblock": "Heme oxygenase 1 (HO-1) serves as a protective gene. The aim of this clinical trial is to\n      evaluate the HO-1 stimulation of resveratrol in healthy humans."
        }, 
        "brief_title": "Reresveratrol Administered to Healthy Male Subjects", 
        "completion_date": {
            "#text": "March 2011", 
            "@type": "Actual"
        }, 
        "condition": [
            "Healthy Subjects", 
            "Heme Oxygenase"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent prior to any study-mandated procedure.\n\n          -  Male patient aged between 18 and 45 years (inclusive) at screening.\n\n          -  No clinically significant findings on the physical examination at screening.\n\n          -  Body mass index (BMI) between 18 and 28 kg/m2 (inclusive) at screening.\n\n          -  Non-smoker (for at least 1 month)\n\n          -  Hematology, clinical chemistry, and urinalysis test results not deviating from the\n             normal range to a clinically relevant extent at screening.\n\n          -  Negative results from urine drug screen at screening.\n\n          -  Ability to communicate well with the investigator, in the local language, and to\n             understand and comply with the requirements of the study.\n\n        Exclusion Criteria:\n\n          -  Known hypersensitivity to resveratrol or any excipients of the resveratrol\n             formulation.\n\n          -  Treatment with any investigational drug within 3 weeks prior to screening.\n\n          -  History or clinical evidence of alcoholism or drug abuse within the 3-year period\n             prior to screening.\n\n          -  History or clinical evidence of any disease and/or existence of any surgical or\n             medical condition, which might interfere with the absorption, distribution,\n             metabolism or excretion of resveratrol.\n\n          -  Smoker\n\n          -  Previous treatment with any prescribed or OTC medications (including herbal medicines\n             such as St John's Wort) within 2 weeks prior to screening.\n\n          -  Regularly intake of resveratrol rich food\n\n          -  Positive results from the hepatitis serology at screening.\n\n          -  Positive results from the HIV serology at screening.\n\n          -  Presumed non-compliance.\n\n          -  Legal incapacity or limited legal capacity at screening."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01768507", 
            "org_study_id": "ClinPharm 754"
        }, 
        "intervention": {
            "arm_group_label": "Resveratrol", 
            "description": "5 g (10 capsules) as single oral dose on day 1", 
            "intervention_name": "Resveratrol", 
            "intervention_type": "Dietary Supplement"
        }, 
        "intervention_browse": {
            "mesh_term": "Resveratrol"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 13, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Vienna", 
                    "country": "Austria", 
                    "zip": "1090"
                }, 
                "name": "Medical University of Vienna"
            }
        }, 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effects of the Dietary Supplement Trans-resveratrol on Heme Oxygenase-1 (HO-1) and Sirtuins Expression in PBMCs in Healthy Male Subjects: A Pilot Study.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Austria: Agency for Health and Food Safety"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "The maximal HO-1 and sirtuin mRNA expression in PBMCs", 
            "safety_issue": "No", 
            "time_frame": "1 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01768507"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Medical University of Vienna", 
            "investigator_full_name": "Daniel Doberer", 
            "investigator_title": "Investigator", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Medical University of Vienna", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Daniel Doberer", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}